Källén B A, Carlsson S S, Bengtsson B K
Tornblad Institute, University of Lund, Sweden.
Eur J Endocrinol. 1995 Feb;132(2):144-6. doi: 10.1530/eje.0.1320144.
With the use of two central health registries in Sweden, the Hospital Discharge Registry and the Medical Birth Registry, we identified 100 infants born of women who had been hospitalized for diabetes insipidus. By checking the medical records of these women, 29 infants were identified whose mothers had diabetes insipidus prior to the pregnancy and had been treated through the pregnancy with desmopressin. These infants had a normal birth weight and gestational length; there was only one congenital malformation identified (a ventricular septum defect with a patent ductus arteriosus and simian lines). This child died at the age of 14 years in a hypophyseal disease. This is the largest material published on desmopressin during pregnancy. The results suggest that maternal diabetes insipidus and treatment with desmopressin during the whole pregnancy does not constitute a major risk for the infant.
利用瑞典的两个中央健康登记处，即医院出院登记处和医疗出生登记处，我们确定了100名母亲曾因尿崩症住院的婴儿。通过检查这些女性的病历，确定了29名婴儿，其母亲在怀孕前就患有尿崩症，并在整个孕期接受了去氨加压素治疗。这些婴儿出生体重和孕周正常；仅发现一例先天性畸形（室间隔缺损伴动脉导管未闭和猿线）。这名儿童在14岁时死于垂体疾病。这是已发表的关于孕期使用去氨加压素的最大规模资料。结果表明，母亲患尿崩症并在整个孕期使用去氨加压素对婴儿不构成重大风险。
